SHARE

France, Innovation, 2017

Telomium continues to develop their product

15th July 2019

Telomium, one of the winners of the French Innovation Journey from Education to Business

After applying the vaccine to three monkeys without secondary reactions, Telomium continues to develop their immunotherapy product against cancer.

Telomium is a biotechnology company developing a therapeutic product for cancer immunotherapy. Their first-in-class ribonucleoprotein vaccine has the ability to mimic a viral attack and induce an auto-immune reaction targeted against any form of cancer, without causing significant side effects. This self-vectored and self-adjuvanted vaccine is prepared from a patented, safe, competitive and scalable yeast-based technology using a breakthrough innovation in the production of recombinant telomerase.

After defining the best use of their product, Telomium plans to raise founds in order so start their regular preclinical development then performing clinical trials in humans and setting a deal with a big pharma group

EIT Health launches seven new members to its community

EIT Health launches seven new members to its community

Enriching the EIT Health network with their collective expertise.

Find out more

Driving personalised medicine forward

Driving personalised medicine forward

The second EP PerMed Round Table convened in Valencia and online.

Find out more

EIT Health’s Open Innovation programme brings together NimBio, Takeda Belgium, KU Leuven to pilot IBD flare detection

EIT Health’s Open Innovation programme brings together NimBio, Takeda Belgium, KU Leuven to pilot IBD flare detection

Transforming unmet clinical needs into scalable solutions.

Find out more